Literature DB >> 22984684

Treatment outcome of conservative surgery plus postoperative radiotherapy for extremity soft tissue sarcoma.

Jieun Lee1, Young Je Park, Dae Sik Yang, Won Sup Yoon, Jung Ae Lee, Chai Hong Rim, Chul Yong Kim.   

Abstract

PURPOSE: To evaluate the treatment outcome and prognostic factor of postoperative radiotherapy for extremity soft tissue sarcoma (STS).
MATERIALS AND METHODS: Forty three patients with extremity STS were treated with conservative surgery and postoperative radiotherapy from January 1981 to December 2010 at Korea University Medical Center. Median total 60 Gy (range, 50 to 74.4 Gy) of radiation was delivered and 7 patients were treated with chemotherapy.
RESULTS: The median follow-up period was 70 months (range, 5 to 302 months). Twelve patients (27.9%) sustained relapse of their disease. Local recurrence occurred in 3 patients (7.0%) and distant metastases developed in 10 patients (23.3%). The 5-year overall survival (OS) was 69.2% and disease free survival was 67.9%. The 5-year local relapse-free survival was 90.7% and distant relapse-free survival was 73.3%. On univariate analysis, no significant prognostic factors were associated with development of local recurrence. Histologic grade (p = 0.005) and stage (p = 0.02) influenced the development of distant metastases. Histologic grade was unique significant prognostic factor for the OS on univariate and multivariate analysis. Severe acute treatment-related complications, Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or 4, developed in 6 patients (14.0%) and severe late complications in 2 patients (4.7%).
CONCLUSION: Conservative surgery with postoperative radiotherapy achieved a satisfactory rate of local control with acceptable complication rate in extremity STS. Most failures were distant metastases that correlate with tumor grade and stage. The majority of local recurrences developed within the field. Selective dose escalation of radiotherapy or development of effective systemic treatment might be considered.

Entities:  

Keywords:  Extremity; Postoperative; Radiotherapy; Sarcoma; Treatment outcome

Year:  2012        PMID: 22984684      PMCID: PMC3429890          DOI: 10.3857/roj.2012.30.2.62

Source DB:  PubMed          Journal:  Radiat Oncol J        ISSN: 2234-1900


  17 in total

1.  Individualizing management of aggressive fibromatoses.

Authors:  M A Spear; L C Jennings; H J Mankin; I J Spiro; D S Springfield; M C Gebhardt; A E Rosenberg; J T Efird; H D Suit
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-02-01       Impact factor: 7.038

2.  Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.

Authors:  P W Pisters; L B Harrison; D H Leung; J M Woodruff; E S Casper; M F Brennan
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

3.  Rhabdomyosarcoma in the pediatric age group.

Authors:  N B Hornback; H Shidnia
Journal:  AJR Am J Roentgenol       Date:  1976-03       Impact factor: 3.959

4.  Association of local recurrence with subsequent survival in extremity soft tissue sarcoma.

Authors:  J J Lewis; D Leung; M Heslin; J M Woodruff; M F Brennan
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.

Authors:  J C Yang; A E Chang; A R Baker; W F Sindelar; D N Danforth; S L Topalian; T DeLaney; E Glatstein; S M Steinberg; M J Merino; S A Rosenberg
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

Review 6.  Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.

Authors:  Marco Fiore; Rosalba Miceli; Chiara Mussi; Salvatore Lo Vullo; Luigi Mariani; Laura Lozza; Paola Collini; Patrizia Olmi; Paolo G Casali; Alessandro Gronchi
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

Review 7.  A systematic overview of radiation therapy effects in soft tissue sarcomas.

Authors:  Hans Strander; Ingela Turesson; Eva Cavallin-Ståhl
Journal:  Acta Oncol       Date:  2003       Impact factor: 4.089

8.  Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results.

Authors:  A J Mundt; A Awan; G S Sibley; M Simon; S J Rubin; B Samuels; W Wong; M Beckett; S Vijayakumar; R R Weichselbaum
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

9.  Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy interval impact on local control?

Authors:  D A Fein; W R Lee; R M Lanciano; B W Corn; S H Herbert; A L Hanlon; J P Hoffman; B L Eisenberg; L R Coia
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

10.  Pattern of local recurrence after conservative surgery and radiotherapy for soft tissue sarcoma.

Authors:  S J Cleator; C Cottrill; C Harmer
Journal:  Sarcoma       Date:  2001
View more
  3 in total

1.  MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas.

Authors:  Katja Schmitz; Hartmut Koeppen; Elke Binot; Jana Fassunke; Helen Künstlinger; Michaela A Ihle; Carina Heydt; Eva Wardelmann; Reinhard Büttner; Sabine Merkelbach-Bruse; Josef Rüschoff; Hans-Ulrich Schildhaus
Journal:  PLoS One       Date:  2015-04-06       Impact factor: 3.240

Review 2.  Intraoperative radiation therapy (IORT) in soft-tissue sarcoma.

Authors:  Falk Roeder; Robert Krempien
Journal:  Radiat Oncol       Date:  2017-01-19       Impact factor: 3.481

3.  Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.

Authors:  Falk Roeder; Burkhard Lehner; Thomas Schmitt; Bernd Kasper; Gerlinde Egerer; Oliver Sedlaczek; Carsten Grüllich; Gunhild Mechtersheimer; Patrick Wuchter; Frank W Hensley; Peter E Huber; Juergen Debus; Marc Bischof
Journal:  BMC Cancer       Date:  2014-05-20       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.